CYP.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 01:59):

Stats
Today's Volume	522 586
Average Volume	137 512
Market Cap	57.48M
EPS	$0 ( 2024-02-26 )
Next earnings date	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.56
ATR14	$0.00300 (0.94%)

Volume Correlation

Long: -0.15 (neutral)

Short: 0.99 (very strong)

Signal:(49.765) Expect same movement, but be aware

Cynata Therapeutics Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cynata Therapeutics Ltd Correlation - Currency/Commodity

-0.13
( neutral )

0.12
( neutral )

0.00
( neutral )

0.25
( neutral )

Cynata Therapeutics Ltd Financials

Annual	2023
Revenue:	$1.65M
Gross Profit:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2023
Revenue:	$1.65M
Gross Profit:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2022
Revenue:	$7.77M
Gross Profit:	$7.49M (96.40 %)
EPS:	$-0.0380

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0590

Financial Reports:

No articles found.

Cynata Therapeutics Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.